Status:
COMPLETED
COVID-19 and Psychotic Symptoms in France
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
Epsylon Laboratory, EA 4556, University Paul Valéry Montpellier 3, France
Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France
Conditions:
Mental Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
Study the impact of containment related to COVID-19 pandemic on psychotic experiences in the general population in France.
Detailed Description
The pandemic of the novel coronavirus disease (COVID-19) has now affected millions of people, including people in France. There are reports in the media about increased stress, anxiety and isolation f...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Individuals from the general population with or without a mental disorder
- French native speaker
- Majority 18 years and more
- Exclusion criteria:
- Patient refusing to participate in research
Exclusion
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2020
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04356885
Start Date
April 1 2020
End Date
August 1 2020
Last Update
December 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Montpellier
Montpellier, France, 34295